Compugen Ltd. announced today financial results for the first quarter ended March 31, 2022. Enrollment continues in the Phase 1 clinical studies for COM701 and COM902. Cash balance of $107 million affirms focus on capital efficiency with bold execution on Compugens DNAM-1 axis hypothesis.
🌍 Compugen Ltd (CGEN) - Form 6-K Filing
Filing Date: 2022-05-16
Accepted: 2022-05-16 07:03:00
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: